Advancements in PARP1 Targeted Nuclear Imaging and Theranostic Probes

Overview

Journal J Clin Med

Specialty General Medicine

Date 2020 Jul 10

PMID 32640708

Citations 19

Authors

Ramya Ambur Sankaranarayanan

Susanne Kossatz

Wolfgang Weber

Mohsen Beheshti

Agnieszka Morgenroth

Felix M Mottaghy

Affiliations

Soon will be listed here.

Abstract

The central paradigm of novel therapeutic approaches in cancer therapy is identifying and targeting molecular biomarkers. One such target is the nuclear DNA repair enzyme Poly-(ADP ribose) polymerase 1 (PARP1). Sensitivity to PARP inhibition in certain cancers such as gBRCA breast and ovarian cancers has led to its exploitation as a target. The overexpression of PARP1 in several types of cancer further evoked interest in its use as an imaging target. While PARP1-targeted inhibitors have fast developed and approved in this past decade, determination of PARP1 expression might help to predict the response to PARP inhibitor treatment. This has the potential of improving prognosis and moving towards tailored therapy options and/or dosages. This review summarizes the recent pre-clinical advancements in imaging and theranostic PARP1 targeted tracers. To assess PARP1 levels, several imaging probes with fluorescent or beta/gamma emitting radionuclides have been proposed and three have advanced to ongoing clinical evaluation. Apart from its diagnostic value in detection of primary tumors as well as metastases, this shall also help in delivering therapeutic radionuclides to PARP1 overexpressing tumors. Henceforth nuclear medicine has now advanced towards conjugating theranostic radionuclides to PARP1 inhibitors. This paves the way for a future of PARP1-targeted theranostics and personalized therapy.

Citing Articles

Theranostics in breast cancer.

Vorster M, Hadebe B, Sathekge M Front Nucl Med. 2024; 3:1236565.

PMID: 39355052 PMC: 11440857. DOI: 10.3389/fnume.2023.1236565.

PARP-1, EpCAM, and FRα as potential targets for intraoperative detection and delineation of endometriosis: a quantitative tissue expression analysis.

Belmonte B, Lorenzo G, Mangogna A, Bortot B, Bertolazzi G, Sammataro S Reprod Biol Endocrinol. 2024; 22(1):92.

PMID: 39085882 PMC: 11293020. DOI: 10.1186/s12958-024-01264-0.

Poly(ADP-ribose) polymerase (PARP)-targeted PET imaging in non-oncology application: a pilot study in preclinical models of nonalcoholic steatohepatitis.

Jeppesen T, Shao T, Chen J, Patel J, Zhou X, Kjaer A Am J Nucl Med Mol Imaging. 2024; 14(1):41-47.

PMID: 38500745 PMC: 10944370.

Imaging Molecular Targets and Metabolic Pathways in Breast Cancer for Improved Clinical Management: Current Practice and Future Perspectives.

Ndlovu H, Lawal I, Mokoala K, Sathekge M Int J Mol Sci. 2024; 25(3).

PMID: 38338854 PMC: 10855575. DOI: 10.3390/ijms25031575.

Peptide receptor radionuclide therapy combinations for neuroendocrine tumours in ongoing clinical trials: status 2023.

di Santo G, Santo G, Sviridenko A, Virgolini I Theranostics. 2024; 14(3):940-953.

PMID: 38250038 PMC: 10797289. DOI: 10.7150/thno.91268.

References

Wilson T, Xavier M, Knight J, Verhoog S, Torres J, Mosley M . PET Imaging of PARP Expression Using F-Olaparib. J Nucl Med. 2018; 60(4):504-510. PMC: 6448459. DOI: 10.2967/jnumed.118.213223. View

Shuhendler A, Cui L, Chen Z, Shen B, Chen M, James M . [F]-SuPAR: A Radiofluorinated Probe for Noninvasive Imaging of DNA Damage-Dependent Poly(ADP-ribose) Polymerase Activity. Bioconjug Chem. 2019; 30(5):1331-1342. DOI: 10.1021/acs.bioconjchem.9b00089. View

Lord C, Ashworth A . PARP inhibitors: Synthetic lethality in the clinic. Science. 2017; 355(6330):1152-1158. PMC: 6175050. DOI: 10.1126/science.aam7344. View

Kossatz S, Pirovano G, Demetrio de Souza Franca P, Strome A, Sunny S, Zanoni D . Validation of the use of a fluorescent PARP1 inhibitor for the detection of oral, oropharyngeal and oesophageal epithelial cancers. Nat Biomed Eng. 2020; 4(3):272-285. PMC: 7136849. DOI: 10.1038/s41551-020-0526-9. View

Makvandi M, Lee H, Puentes L, Reilly S, Rathi K, Weng C . Targeting PARP-1 with Alpha-Particles Is Potently Cytotoxic to Human Neuroblastoma in Preclinical Models. Mol Cancer Ther. 2019; 18(7):1195-1204. PMC: 6606392. DOI: 10.1158/1535-7163.MCT-18-0837. View

Jahangiri A, Chin A, Flanigan P, Chen R, Bankiewicz K, Aghi M . Convection-enhanced delivery in glioblastoma: a review of preclinical and clinical studies. J Neurosurg. 2016; 126(1):191-200. PMC: 5571827. DOI: 10.3171/2016.1.JNS151591. View

Meng X, Zhao Y, Han B, Zha C, Zhang Y, Li Z . Dual functionalized brain-targeting nanoinhibitors restrain temozolomide-resistant glioma via attenuating EGFR and MET signaling pathways. Nat Commun. 2020; 11(1):594. PMC: 6992617. DOI: 10.1038/s41467-019-14036-x. View

Reiner T, Keliher E, Earley S, Marinelli B, Weissleder R . Synthesis and in vivo imaging of a 18F-labeled PARP1 inhibitor using a chemically orthogonal scavenger-assisted high-performance method. Angew Chem Int Ed Engl. 2011; 50(8):1922-5. PMC: 3471140. DOI: 10.1002/anie.201006579. View

Tang J, Salloum D, Carney B, Brand C, Kossatz S, Sadique A . Targeted PET imaging strategy to differentiate malignant from inflamed lymph nodes in diffuse large B-cell lymphoma. Proc Natl Acad Sci U S A. 2017; 114(36):E7441-E7449. PMC: 5594659. DOI: 10.1073/pnas.1705013114. View

10.

Jacobson O, Chen X . Interrogating tumor metabolism and tumor microenvironments using molecular positron emission tomography imaging. Theranostic approaches to improve therapeutics. Pharmacol Rev. 2013; 65(4):1214-56. PMC: 3799232. DOI: 10.1124/pr.113.007625. View

11.

Gonzales J, Kossatz S, Roberts S, Pirovano G, Brand C, Perez-Medina C . Nanoemulsion-Based Delivery of Fluorescent PARP Inhibitors in Mouse Models of Small Cell Lung Cancer. Bioconjug Chem. 2018; 29(11):3776-3782. PMC: 6548450. DOI: 10.1021/acs.bioconjchem.8b00640. View

12.

Jannetti S, Carlucci G, Carney B, Kossatz S, Shenker L, Carter L . PARP-1-Targeted Radiotherapy in Mouse Models of Glioblastoma. J Nucl Med. 2018; 59(8):1225-1233. PMC: 6071508. DOI: 10.2967/jnumed.117.205054. View

13.

Hanna C, Kurian K, Williams K, Watts C, Jackson A, Carruthers R . Pharmacokinetics, safety, and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trial. Neuro Oncol. 2020; 22(12):1840-1850. PMC: 7746945. DOI: 10.1093/neuonc/noaa104. View

14.

Pirovano G, Jannetti S, Carter L, Sadique A, Kossatz S, Guru N . Targeted Brain Tumor Radiotherapy Using an Auger Emitter. Clin Cancer Res. 2020; 26(12):2871-2881. PMC: 7299758. DOI: 10.1158/1078-0432.CCR-19-2440. View

15.

Balasubramaniam S, Beaver J, Horton S, Fernandes L, Tang S, Horne H . FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious Mutation-Associated Advanced Ovarian Cancer. Clin Cancer Res. 2017; 23(23):7165-7170. DOI: 10.1158/1078-0432.CCR-17-1337. View

16.

Laird J, Lok B, Carney B, Kossatz S, de Stanchina E, Reiner T . Positron-Emission Tomographic Imaging of a Fluorine 18-Radiolabeled Poly(ADP-Ribose) Polymerase 1 Inhibitor Monitors the Therapeutic Efficacy of Talazoparib in SCLC Patient-Derived Xenografts. J Thorac Oncol. 2019; 14(10):1743-1752. PMC: 6764879. DOI: 10.1016/j.jtho.2019.05.032. View

17.

Demetrio de Souza Franca P, Roberts S, Kossatz S, Guru N, Mason C, Zanoni D . Fluorine-18 labeled poly (ADP-ribose) polymerase1 inhibitor as a potential alternative to 2-deoxy-2-[F]fluoro-d-glucose positron emission tomography in oral cancer imaging. Nucl Med Biol. 2020; 84-85:80-87. PMC: 7253343. DOI: 10.1016/j.nucmedbio.2020.01.004. View

18.

Ison G, Howie L, Amiri-Kordestani L, Zhang L, Tang S, Sridhara R . FDA Approval Summary: Niraparib for the Maintenance Treatment of Patients with Recurrent Ovarian Cancer in Response to Platinum-Based Chemotherapy. Clin Cancer Res. 2018; 24(17):4066-4071. DOI: 10.1158/1078-0432.CCR-18-0042. View

19.

Keliher E, Klubnick J, Reiner T, Mazitschek R, Weissleder R . Efficient acid-catalyzed (18) F/(19) F fluoride exchange of BODIPY dyes. ChemMedChem. 2014; 9(7):1368-73. PMC: 4145401. DOI: 10.1002/cmdc.201300506. View

20.

Carney B, Carlucci G, Salinas B, Di Gialleonardo V, Kossatz S, Vansteene A . Non-invasive PET Imaging of PARP1 Expression in Glioblastoma Models. Mol Imaging Biol. 2015; 18(3):386-92. PMC: 4841747. DOI: 10.1007/s11307-015-0904-y. View